- Home
- IVVD
IVVD
Invivyd Inc.
as 12-20-2024 4:00pm EST
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 116.8M | IPO Year: | 2021 |
| Target Price: | $7.89 | AVG Volume (30 days): | 981.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $5.20 | Next Earning Date: | 11-14-2024 |
| Revenue: | $11,564,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 486.65% |
Stock Insider Trading Activity of Invivyd Inc. (IVVD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | IVVD | Director | Dec 12 '24 | Sell | $0.52 | 190,359 | $103,384.58 | 4,077,679 | |
| MCGUIRE TERRANCE | IVVD | Director | Dec 9 '24 | Sell | $0.60 | 485,400 | $289,377.44 | 4,077,679 |
Latest Invivyd Inc. News
IVVD Breaking Stock News: Dive into IVVD Ticker-Specific Updates for Smart Investing
Medical Device Network
5 days ago
Adagio Medical announces Todd Usen as new CEO and director
MT Newswires
6 days ago
Adagio Medical Appoints Todd Usen as CEO
Thomson Reuters StreetEvents
a month ago
Q3 2024 Invivyd Inc Earnings Call
GuruFocus.com
a month ago
Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
Zacks
a month ago
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
a month ago
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
a month ago
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
GuruFocus.com
a month ago
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect
Compare IVVD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IVVD Invivyd Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.